Effectivnes of edaravone on ischemic stroke
Phase 3
Not yet recruiting
- Conditions
- Ischemic stroke.Cerebral infarction
- Registration Number
- IRCT20240224061102N1
- Lead Sponsor
- Yasouj University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Participants with ischemic stroke based on clinical symptoms and CT scan
Participants with ischemic stroke and NIHSS score of 16
Exclusion Criteria
Unwillingness to participate
Significant cognitive and neurological impairments
Presence of hemorrhagic stroke
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie edaravone's neuroprotective effects in ischemic stroke?
How does edaravone compare to standard-of-care treatments like alteplase in acute ischemic stroke outcomes?
Which biomarkers are associated with response to edaravone in cerebral infarction patients?
What adverse events are reported with edaravone use in phase III ischemic stroke trials?
Are there combination therapies involving edaravone and anti-oxidants for cerebral infarction treatment?